BNTX - BioNTech SE - ADR
IEX Last Trade
88.25
0.650 0.737%
Share volume: 595,074
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$87.60
0.65
0.74%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-07 | 2023-03-27 | 2023-05-08 | 2023-08-07 | 2023-11-06 | 2024-03-20 | 2024-05-06 | |
| Assets | |||||||||
| Total Assets | 22.115 B | 22.206 B | 24.970 B | 24.073 B | 24.161 B | 23.496 B | 25.435 B | 24.038 B | |
| Current Assets | 21.124 B | 20.842 B | 23.515 B | 21.901 B | 20.887 B | 19.837 B | 21.588 B | 19.736 B | |
| Inventories | 384.373 M | 288.888 M | 471.537 M | 462.410 M | 487.991 M | 439.824 M | 395.455 M | 373.036 M | |
| Other Current Assets | 128.264 M | 236.069 M | 495.242 M | 1.164 B | 2.109 B | 3.000 B | 5.915 B | 7.897 B | |
| Short Term Investments | 128.264 M | 236.069 M | 495.242 M | 1.164 B | 2.109 B | 3.000 B | 5.915 B | 7.897 B | |
| Total Receivables | 10.854 B | 7.163 B | 7.665 B | 7.033 B | 2.889 B | 2.118 B | 2.383 B | 1.771 B | |
| Current Cash | 9.758 B | 13.155 B | 14.883 B | 13.241 B | 15.400 B | 14.279 B | 12.895 B | 9.695 B | |
| Total Non-current Assets | 990.255 M | 1.364 B | 1.456 B | 2.173 B | 3.274 B | 3.659 B | 3.846 B | 4.301 B | |
| Property Plant Equipment | 439.463 M | 478.704 M | 653.458 M | 696.941 M | 751.282 M | 771.200 M | 837.123 M | 866.816 M | |
| Other Assets | 319.353 M | 326.714 M | 320.293 M | 795.507 M | 1.717 B | 1.576 B | 1.629 B | 2.051 B | |
| Intangible Assets | 231.439 M | 221.664 M | 235.661 M | 412.800 M | 545.063 M | 704.121 M | 888.973 M | 887.445 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 386.817 M | 400.762 M | 398.200 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 22.115 B | 22.206 B | 24.970 B | 24.073 B | 24.161 B | 23.496 B | 25.435 B | 24.038 B | |
| Total liabilities | 4.521 B | 4.208 B | 3.458 B | 1.978 B | 2.521 B | 2.476 B | 3.052 B | 2.472 B | |
| Total current liabilities | 4.102 B | 3.878 B | 3.165 B | 1.691 B | 1.977 B | 1.912 B | 2.289 B | 1.734 B | |
| Accounts Payable | 304.300 M | 290.554 M | 218.928 M | 32.601 M | 248.507 M | 235.624 M | 391.365 M | 322.707 M | |
| Other liabilities | 98.262 M | 90.743 M | 97.075 M | 92.787 M | 357.106 M | 347.246 M | 507.669 M | 473.261 M | |
| Current long term debt | 33.765 M | 36.258 M | 38.615 M | 40.778 M | 41.961 M | 42.321 M | 31.066 M | 33.804 M | |
| Long term debt | 215.968 M | 232.247 M | 189.001 M | 187.973 M | 181.651 M | 171.296 M | 211.160 M | 221.402 M | |
| Other liabilities | 98.262 M | 90.743 M | 97.075 M | 92.787 M | 357.106 M | 347.246 M | 507.669 M | 473.261 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 17.594 B | 17.998 B | 21.513 B | 22.096 B | 21.640 B | 21.020 B | 22.383 B | 21.566 B | |
| Common stock | 242.670 M | 240.230 M | 245.832 M | 242.609 M | 241.013 M | 239.701 M | 239.077 M | 240.534 M | |
| Retained earnings | 15.439 B | 16.222 B | 20.201 B | 21.082 B | 20.812 B | 20.426 B | 21.849 B | 21.004 B |